Arbutus Biopharma Corporation (ABUS)

Market Cap	608.27M
Revenue (ttm)	6.74M
Net Income (ttm)	-76.70M
Shares Out	189.49M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,537,179
Open	3.180
Previous Close	3.210
Day's Range	3.160 - 3.260
52-Week Range	2.210 - 4.720
Beta	1.78
Analysts	Strong Buy
Price Target	5.50 (+71.34%)
Earnings Date	Nov 6, 2024

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Michael McElhaugh
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: ABUS
• Website: https://www.arbutusbio.com

Financial Performance

In 2023, Arbutus Biopharma's revenue was $18.14 million, a decrease of -53.51% compared to the previous year's $39.02 million. Losses were -$72.85 million, 4.89% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 71.34% from the latest price.

Price Target

$5.5

(71.34% upside)

Analyst Consensus: Strong Buy